Viewing nowCombinationOlpro Tablet 20/20 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Hana Pharm Co., Ltd.

MFDS item code 202003976 · Approved 2020.05.28 · Insurance code 657807390
Treatment of hypertension, treatment of dyslipidemia, suppression of atherosclerosis progression and cardiovascular disease risk
This medication is used for patients who require simultaneous administration of Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil is utilized for the treatment of essential hypertension, while Rosuvastatin is used as an adjunct when hypercholesterolemia and hyperlipidemia cannot be managed by diet and exercise alone. Additionally, Rosuvastatin is prescribed for various types of dyslipidemia such as familial hypercholesterolemia and dysbetalipoproteinemia. This medication helps to lower total cholesterol and LDL cholesterol, slowing down the progression of atherosclerosis and reducing the risk of cardiovascular diseases. It is particularly effective in reducing the risk of stroke, myocardial infarction, and vascular revascularization procedures in middle-aged adults with elevated levels of high-sensitivity C-reactive protein and cardiovascular risk factors. Therefore, this medication improves cardiovascular health by managing both hypertension and hyperlipidemia.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.
Safety and efficacy have not been established in children under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, if pregnancy is confirmed, it must be discontinued immediately. This medication should not be used in women who are allergic to any component, pregnant or breastfeeding, patients with severely impaired renal function, or those with severe liver disease. Patients with decreased blood volume or those taking significant doses of diuretics should be closely monitored for hypotension upon initial dosing. Patients with impaired renal function or kidney transplant recipients, as well as those with renovascular hypertension, should have their renal function and serum electrolyte levels regularly checked during treatment. Due to the risk of hyperkalemia, potassium levels in the blood should be checked periodically, and caution is advised in patients with cardiac or aortic abnormalities. Muscle-related adverse reactions may occur; if symptoms of myalgia or muscle weakness arise, the physician should be notified immediately. Patients with a history of excessive alcohol consumption or liver disease should be monitored closely and undergo regular liver function tests while using this medication. Specifically, the Rosuvastatin component of this medication may cause serious side effects such as liver damage, myopathy, and rarely, rhabdomyolysis. This medication may interact with other drugs, so if taking other medications, patients must inform their physician or pharmacist. Women who are pregnant or planning to become pregnant should use appropriate contraception, and breastfeeding should be ceased if using this medication. Elderly patients may have increased concentration of this medication in their bodies, necessitating dosage adjustments and careful monitoring. Overdose may lead to symptoms such as hypotension and palpitations; as there are no specific antidotes, symptomatic treatment should be administered. This medication has not been established for safety and efficacy in children and should not be used by them. Store this medication out of reach of children, and do not transfer it to other containers.
Increased ALT, increased AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial swelling, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption similar intestinal disease, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness including positional vertigo, palpitations, elevated blood pressure, low back pain, increased serum creatinine, diarrhea, pruritus, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia including myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders including insomnia and nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius.
White or yellowish round film-coated tablets
30 tablets/box [(10 tablets/Alu-Alu) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Hana Pharm Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.